



Cervical Cancer Elimination Initiative (CCEI) Team
Relevant publications to contribute to the cervical cancer elimination initiative

PUBLICATIONS ON HPV VACCINATION: EVIDENCE OF ONE-DOSE PROTECTION AND EFFICACY OF NEW VACCINES

1. Lakshmanasamy R, Palaniraja S, Basu P. "Beyond promises: Why India must act now to deliver HPV vaccination". *Vaccine*. 2026 Jan 1;69:127974. [doi: 10.1016/j.vaccine.2025.127974](https://doi.org/10.1016/j.vaccine.2025.127974). [PMID: 41223689](https://pubmed.ncbi.nlm.nih.gov/41223689/).
2. Burdier FR, Bosch FX, Waheed DE, Teblich L, Poljak M, Baay M, de Sanjosé S, Bardou M, Baussano I, Man I, Franco EL, Vorsters A. Accelerating HPV-related cancer elimination - a meeting report. *BMC Proc*. 2025 Aug 29;19(Suppl 19):22. [doi: 10.1186/s12919-025-00337-1](https://doi.org/10.1186/s12919-025-00337-1). [PMID: 40877872](https://pubmed.ncbi.nlm.nih.gov/40877872/).
3. Arbyn M, Rousta P, Bruni L, Schollin Ask L, Basu P. Linkage of individual-patient data confirm protection of prophylactic human papillomavirus vaccination against invasive cervical cancer. *J Natl Cancer Inst*. 2024 Jun 7;116(6):775-778. [doi: 10.1093/jnci/djae042](https://doi.org/10.1093/jnci/djae042). [PMID: 38501990](https://pubmed.ncbi.nlm.nih.gov/38501990/).
4. Arroyo Mühr LS, Gini A, Yilmaz E, Hassan SS, Lagheden C, Hultin E, Garcia Serrano A, Ure AE, Andersson H, Merino R, Elfström KM, Baussano I, Dillner J. Concomitant human papillomavirus (HPV) vaccination and screening for elimination of HPV and cervical cancer. *Nat Commun*. 2024;15(1):3679. [doi: 10.1038/s41467-024-47909-x](https://doi.org/10.1038/s41467-024-47909-x). [PMID: 38693149](https://pubmed.ncbi.nlm.nih.gov/38693149/).
5. Fokom Domgue J, Dille I, Kapambwe S, Yu R, Gnanngnon F, Chinula L, Murenzi G, Mbatani N, Pande M, Sidibe F, Kamgno J, Traore B, Fazazi HE, Diop M, Tebeu PM, Diomande MI, Lecuru F, Adewole I, Plante M, Basu P, Dangou JM, Shete S. HPV vaccination in Africa in the COVID-19 era: a cross-sectional survey of healthcare providers' knowledge, training, and recommendation practices. *Front Public Health*. 2024 Jan 17;12:1343064. [doi: 10.3389/fpubh.2024.1343064](https://doi.org/10.3389/fpubh.2024.1343064). [PMID: 38299075](https://pubmed.ncbi.nlm.nih.gov/38299075/).
6. Kamuyu G, Coelho da Silva F, Tenet V, Schussler J, Godi A, Herrero R, Porras C, Mirabello L, Schiller JT, Sierra MS, Kreimer AR, Clifford GM, Beddows S. Global evaluation of lineage-specific human papillomavirus capsid antigenicity using antibodies elicited by natural infection. *Nat Commun*. 2024;15(1):1608. [doi: 10.1038/s41467-024-45807-w](https://doi.org/10.1038/s41467-024-45807-w). [PMID: 38383518](https://pubmed.ncbi.nlm.nih.gov/38383518/).
7. Malvi SG, Esmey PO, Muwonge R, Joshi S, Poli URR, Lucas E, Verma Y, Lucksom PG, Shah A, Patel B, Zomawia E, Pimple S, Jayant K, Hingmire S, Chiwate A, Divate U, Vashist S, Mishra G, Jadhav R, Siddiqi M, Sauvaget C, Sankaran S, Kannan T, Shastri SS, Pillai MR, Anantharaman D, Bhatla N, Sankaranarayanan R, Basu P. A prospective cohort study comparing efficacy of 1 dose of quadrivalent human papillomavirus vaccine to 2 and 3 doses at an average follow up of 12 years postvaccination. *J Natl Cancer Inst Monogr*. 2024;2024(67):317-28. [doi: 10.1093/jncimonographs/lgae042](https://doi.org/10.1093/jncimonographs/lgae042). [PMID: 39529521](https://pubmed.ncbi.nlm.nih.gov/39529521/).



8. Man I, Georges D, Basu P, Baussano I. Leveraging single-dose human papillomavirus vaccination dose-efficiency to attain cervical cancer elimination in resource-constrained settings. *J Natl Cancer Inst Monogr.* 2024;2024(67):400-9. [doi: 10.1093/jncimonographs/lgae035](https://doi.org/10.1093/jncimonographs/lgae035). [PMID: 39529528](https://pubmed.ncbi.nlm.nih.gov/39529528/).
9. Singini MG, Muchengeti M, Sitas F, Chen WC, Combes JD, Waterboer T, Clifford GM. Antibodies against high-risk human papillomavirus proteins as markers for noncervical HPV-related cancers in a Black South African population, according to HIV status. *Int J Cancer.* 2024;155(2):251-60. [doi: 10.1002/ijc.34919](https://doi.org/10.1002/ijc.34919). [PMID: 38577820](https://pubmed.ncbi.nlm.nih.gov/38577820/).
10. Wei F, Georges D, Man I, Baussano I, Clifford GM. Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature. *Lancet.* 2024;404(10451):435-44. [doi: 10.1016/s0140-6736\(24\)01097-3](https://doi.org/10.1016/s0140-6736(24)01097-3). [PMID: 39097395](https://pubmed.ncbi.nlm.nih.gov/39097395/).
11. Whitworth HS, Mounier-Jack S, Choi EM, Gallagher KE, Howard N, Kelly H, Mbwanji G, Kreimer AR, Basu P, Barnabas R, Drolet M, Brisson M, Watson-Jones D. Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to multidose vaccination regimens or no vaccination: An updated systematic review of evidence from clinical trials. *Vaccine X.* 2024 Apr 16;19:100486. [doi: 10.1016/j.jvacx.2024.100486](https://doi.org/10.1016/j.jvacx.2024.100486). [PMID: 38873638](https://pubmed.ncbi.nlm.nih.gov/38873638/).
12. Burger E, Baussano I, Kim JJ, Laprise JF, Berkhof J, Schiller JT, Canfell K, Prem K, Brisson M, Jit M, Barnabas RV. Recent economic evaluation of 1-dose HPV vaccination uses unsupported assumptions. *Vaccine.* 2023 Apr 17;41(16):2648-2649. [doi: 10.1016/j.vaccine.2022.07.022](https://doi.org/10.1016/j.vaccine.2022.07.022). [PMID: 35941035](https://pubmed.ncbi.nlm.nih.gov/35941035/).
13. IARC (2023). Protection from a Single Dose of HPV Vaccine: A major public health impact from IARC studies of vaccine efficacy (IARC Evidence Summary Briefs, No. 4). Lyon, France: International Agency for Research on Cancer. Available from: https://www.iarc.who.int/wp-content/uploads/2023/04/IARC_Evidence_Summary_Brief_4.pdf.
14. Joshi S, Anantharaman D, Muwonge R, Bhatla N, Panicker G, Butt J, Rani Reddy Poli U, Malvi SG, Esmay PO, Lucas E, Verma Y, Shah A, Zomawia E, Pimple S, Jayant K, Hingmire S, Chiwate A, Divate U, Vashist S, Mishra G, Jadhav R, Siddiqi M, Sankaran S, Pillai Rameshwari Ammal Kannan T, Kartha P, Shastri SS, Sauvaget C, Radhakrishna Pillai M, Waterboer T, Müller M, Sehr P, Unger ER, Sankaranarayanan R, Basu P. Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination. *Vaccine.* 2023 Jan 4;41(1):236-245. [doi: 10.1016/j.vaccine.2022.11.044](https://doi.org/10.1016/j.vaccine.2022.11.044). [PMID: 36446654](https://pubmed.ncbi.nlm.nih.gov/36446654/).
15. Kutz JM, Rausche P, Gheit T, Puradiredja DI, Fusco D. Barriers and facilitators of HPV vaccination in sub-Saharan Africa: a systematic review. *BMC Public Health.* 2023 May 26;23(1):974. [doi: 10.1186/s12889-023-15842-1](https://doi.org/10.1186/s12889-023-15842-1). [PMID: 37237329](https://pubmed.ncbi.nlm.nih.gov/37237329/).
16. Man I, Georges D, Bonjour M, Baussano I. Approximating missing epidemiological data for cervical cancer through Footprinting: A case study in India. *Elife.* 2023 May 25;12:e81752. [doi: 10.7554/eLife.81752](https://doi.org/10.7554/eLife.81752). [PMID: 37227260](https://pubmed.ncbi.nlm.nih.gov/37227260/).



17. Man I, Georges D, de Carvalho TM, Ray Saraswati L, Bhandari P, Kataria I, Siddiqui M, Muwonge R, Lucas E, Berkhof J, Sankaranarayanan R, Bogaards JA, Basu P, Baussano I. Evidence-based impact projections of single-dose human papillomavirus vaccination in India: a modelling study. *Lancet Oncol*. 2022 Nov;23(11):1419-1429. [doi: 10.1016/S1470-2045\(22\)00543-5](https://doi.org/10.1016/S1470-2045(22)00543-5). [PMID: 36174583](https://pubmed.ncbi.nlm.nih.gov/36174583/).
18. Man I, Georges D, Sankaranarayanan R, Basu P, Baussano I. Building resilient cervical cancer prevention through gender-neutral HPV vaccination. *Elife*. 2023 Jul 24;12:e85735. [doi: 10.7554/eLife.85735](https://doi.org/10.7554/eLife.85735). [PMID: 37486822](https://pubmed.ncbi.nlm.nih.gov/37486822/).
19. Waheed DE, Burdier FR, Eklund C, Baussano I, Mariz FC, Téblick L, Mugo N, Watson-Jones D, Stanley M, Baay M, Vorsters A. An update on one-dose HPV vaccine studies, immunobridging and humoral immune responses - A meeting report. *Prev Med Rep*. 2023 Aug 14;35:102368. [doi: 10.1016/j.pmedr.2023.102368](https://doi.org/10.1016/j.pmedr.2023.102368). [PMID: 37680853](https://pubmed.ncbi.nlm.nih.gov/37680853/).
20. Sayinzoga F, Tenet V, Heideman DAM, Sibomana H, Umulisa MC, Franceschi S, Hakizimana JD, Clifford GM, Baussano I. Human papillomavirus vaccine effect against human papillomavirus infection in Rwanda: evidence from repeated cross-sectional cervical-cell-based surveys. *Lancet Glob Health*. 2023 Jul;11(7):e1096-e1104. [doi: 10.1016/S2214-109X\(23\)00193-6](https://doi.org/10.1016/S2214-109X(23)00193-6). [PMID: 37207683](https://pubmed.ncbi.nlm.nih.gov/37207683/).
21. Schuind AE, Rees H, Schiller J, Mugo N, Dull P, Barnabas R, Clifford GM, Liu G, Madhi SA, Morse RB, Moscicki AB, Palefsky JM, Plotkin S, Sierra MS, Slifka MK, Vorsters A, Kreimer AR, Didierlaurent AM. State-of-the-Science of human papillomavirus vaccination in women with human immunodeficiency Virus: Summary of a scientific workshop. *Prev Med Rep*. 2023 Jul 19;35:102331. [doi: 10.1016/j.pmedr.2023.102331](https://doi.org/10.1016/j.pmedr.2023.102331). [PMID: 37576844](https://pubmed.ncbi.nlm.nih.gov/37576844/).
22. Sharma H, Parekh S, Pujari P, Shewale S, Desai S, Bhatla N, Joshi S, Pimple S, Kawade A, Balasubramani L, Thomas A, Suri V, Lalwani S, Uday R, Kamath V, Mandal R, Rajeswar A, Peedicayil A, Poli UR, Banerjee D, Sankaranarayanan R, Basu P, Muwonge R, Gairola S, Dogar V, Rao H, Shaligram U. Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial. *Lancet Oncol*. 2023 Dec;24(12):1321-1333. [doi: 10.1016/S1470-2045\(23\)00480-1](https://doi.org/10.1016/S1470-2045(23)00480-1). [PMID: 37949086](https://pubmed.ncbi.nlm.nih.gov/37949086/).
23. Escriva-Boulley G, Mandrik O, Préau M, Herrero R, Villain P. Cognitions and behaviours of general practitioners in France regarding HPV vaccination: A theory-based systematic review. *Prev Med*. 2021 Feb;143:106323. [doi: 10.1016/j.ypmed.2020.106323](https://doi.org/10.1016/j.ypmed.2020.106323). [PMID: 33171178](https://pubmed.ncbi.nlm.nih.gov/33171178/).
24. Basu P. Example 2. HPV vaccination and screening for cervical cancer. In S. Vaccarella, J. Lortet-Tieulent, R. Saracci, D.I. Conway, K. Straif, C.P. Wild (eds). *Reducing social inequalities in cancer: evidence and priorities for research*. IARC Scientific Publications No. 168, 2019. Available from : [IARC Publications Website - Reducing Social Inequalities in Cancer: Evidence and Priorities for Research](https://publications.iarc.fr/publication/168).



IMPLEMENTATION AND SURVEILLANCE OF SCREENING PROGRAMMES

1. Andoh J, Taghavi K, Moono M, Basu P, Madliwa T, Mwanahamuntu MH, Low N, Manasyan A, Rohner E. Cervical intraepithelial neoplasia progression and regression among women living with HIV in Zambia. *HIV Med.* 2025 Dec;26(12):1939-1949. [doi: 10.1111/hiv.70134](https://doi.org/10.1111/hiv.70134). [PMID: 41194500](https://pubmed.ncbi.nlm.nih.gov/41194500/).
2. Basu P. Progress toward cervical cancer elimination: global disparities and China's contributions. *Cancer Biol Med.* 2025 Sep 29;22(9):991–6. [doi: 10.20892/j.issn.2095-3941.2025.0428](https://doi.org/10.20892/j.issn.2095-3941.2025.0428). [PMID: 41024615](https://pubmed.ncbi.nlm.nih.gov/41024615/).
3. Chandran A, Kataria I, Oswal K, Isaac R, Mallafré-Larrosa M, Palaniraja S, Swaminathan R, Rebello R, Vani NV, Vijayan B, Kuriakose M, Purushotham A, Sankaranarayanan R, Selvam J, Sullivan R, Basu P. Co-designing and evaluation of a context-appropriate strategy to improve access to early detection and care of oral, breast and cervical cancers in rural India: a formative phase implementation research protocol. *Ecancermedicalscience.* 2025 Feb 13;19:1849. [doi: 10.3332/ecancer.2025.1849](https://doi.org/10.3332/ecancer.2025.1849). [PMID: 40259906](https://pubmed.ncbi.nlm.nih.gov/40259906/).
4. Chandran A, Mackie A, Sasieni P, Arbyn M, Carvalho AL, Chauvet C, Prendiville W, Weiderpass E, Basu P; CervScreen Technical Working Group. Technical, legal and ethical framework of cancer audit in cervical screening - Summary of best practices for organised programmes delineated through an expert group consultation. *Int J Cancer.* 2025 Jul 1;157(1):32-40. [doi: 10.1002/ijc.35403](https://doi.org/10.1002/ijc.35403). [PMID: 40208390](https://pubmed.ncbi.nlm.nih.gov/40208390/).
5. Joshi S, Muwonge R, Bhosale R, Chaudhari P, Kulkarni V, Mandolkar M, Deodhar K, Kand S, Phadke N, Rajan S, Kumar BK, Sankaranarayanan R, Basu P. A randomised controlled non-inferiority trial to compare the efficacy of 'HPV screen, triage and treat' with 'HPV screen and treat' approach for cervical cancer prevention among women living with HIV. *Nat Commun.* 2025 Feb 22;16(1):1888. [doi: 10.1038/s41467-025-56926-3](https://doi.org/10.1038/s41467-025-56926-3). [PMID: 39987163](https://pubmed.ncbi.nlm.nih.gov/39987163/).
6. Kataria I, Selmouni F, Duggan C, Sullivan R, Purushotham A, Sankaranarayanan R, Taghavi K, Basu P. Application of implementation science methods and theories for cancer control planning in low-income and middle-income countries: a scoping review. *BMJ Open.* 2025 Oct 27;15(10):e108755. [doi: 10.1136/bmjopen-2025-108755](https://doi.org/10.1136/bmjopen-2025-108755). [PMID: 41145253](https://pubmed.ncbi.nlm.nih.gov/41145253/).
7. Lucas E, Dimitrova N, Tomatis M, Sheridan B, Arbyn M, Heijnsdijk E, Armaroli P, Martens P, Partanen VM, Chandran A, Carvalho AL, Yared W, Khatchadourian A, Senore C, Basu P. Creating a data processing warehouse to support performance monitoring of cancer screening programmes in Europe using a common set of indicators. *Eur J Public Health.* 2025 Oct 1;35(5):977-983. [doi: 10.1093/eurpub/ckaf119](https://doi.org/10.1093/eurpub/ckaf119). [PMID: 40633063](https://pubmed.ncbi.nlm.nih.gov/40633063/).
8. Luizaga CTM, Câmara AB, Cury LCPB, Lopez RVM, Contreras CAH, Basu P, Wünsch-Filho V, Carvalho AL. Barriers and attitudes toward cervical cancer screening among eligible women. *Cancer Causes Control.* 2025 Dec;36(12):1763-1774. [doi: 10.1007/s10552-025-02058-4](https://doi.org/10.1007/s10552-025-02058-4). [PMID: 40864370](https://pubmed.ncbi.nlm.nih.gov/40864370/).
9. Mosquera I, Chandran A, Rol ML, Mesmin Olivier AY, Herve Julius YB, Asnake TM, Mugabe FR, Kebirungi B, Chaila MJ, Pupwe G, Guzha BT, Simango N, Kapambwe S, Dangou JM, Basu P, Carvalho AL. Assessment of barriers to the cervical cancer continuum and existing interventions in 5 African countries. *BMC Public Health.* 2025 Dec 4. [doi: 10.1186/s12889-025-25733-2](https://doi.org/10.1186/s12889-025-25733-2). [PMID: 41345850](https://pubmed.ncbi.nlm.nih.gov/41345850/).



10. Mosquera I, Chandran A, Basu P. CervScreen-SARA: a protocol and tools to assess availability and readiness to deliver HPV-based screening. *HPV World*. 2025; January:288.
11. Mosquera I, Theriault H, Meunier D, Basu P, Carvalho AL. Development and pilot testing of INTERVENER, a web-based tool to match barriers to the cancer continuum organization to evidence-based interventions. *BMC Health Serv Res*. 2025 Jan 9;25(1):47. [doi: 10.1186/s12913-024-12171-w](https://doi.org/10.1186/s12913-024-12171-w). [PMID: 39789584](https://pubmed.ncbi.nlm.nih.gov/39789584/).
12. Nessa A, Uddin SMN, Lucas E, Nag P, Palaniraja S, Rol M, Khan MAS, Khan MAH, Begum SA, Afroz R, Ferdous NE, Muwonge R, Basu P. Implementation of an electronic health information system using DHIS2 tracker to manage and evaluate the National cervical screening programme in Bangladesh. *BMC Public Health*. 2025 May 5;25(1):1649. [doi: 10.1186/s12889-025-22668-6](https://doi.org/10.1186/s12889-025-22668-6). [PMID: 40325476](https://pubmed.ncbi.nlm.nih.gov/40325476/).
13. Ortega Llobet M, Gray P, Baussano I, Elfström KM, Eriksson T, Lagheden C, Nieminen P, Söderlund-Strand A, Dillner J, Pimenoff VN, Lehtinen M. Controlled trial of cervical cancer screening frequency among human-papillomavirus-vaccinated women. *Int J Cancer*. 2025 Nov 7. [doi: 10.1002/ijc.70229](https://doi.org/10.1002/ijc.70229). [PMID: 41203578](https://pubmed.ncbi.nlm.nih.gov/41203578/).
14. Oswal K, Gaurav K, Pradhan A, Ramachandran V, Sebastian P, Basu P. Current Status of Implementation of Cancer Screening Programme in India: A Review of Policies and Practice. *Asian Pac J Cancer Prev*. 2025 Apr 1;26(4):1117-1128. [doi: 10.31557/APJCP.2025.26.4.1117](https://doi.org/10.31557/APJCP.2025.26.4.1117). [PMID: 40302063](https://pubmed.ncbi.nlm.nih.gov/40302063/).
15. Palaniraja S, Taghavi K, Kataria I, Oswal K, Vani NV, Liji AA, Parekh H, Isaac R, Kuriakose M, Swaminathan R, Rebello R, Purushotham A, Basu P, Sullivan R, Chandran A. Barriers and contributions of rural community health workers in enabling cancer early detection and subsequent care in India: a qualitative study. *BMC Public Health*. 2025 Apr 24;25(1):1527. [doi: 10.1186/s12889-025-22735-y](https://doi.org/10.1186/s12889-025-22735-y). [PMID: 40275281](https://pubmed.ncbi.nlm.nih.gov/40275281/).
16. Ramírez AT, Clifford GM, Dillner J, Kuhn L, Arbyn M, Bhatla N, Wentzensen N, Sasien P, Abraham P, Rol ML, Almonte M, Basu P. Reflections Regarding Validation of New HPV Tests With Reduced HPV Genotypes: Report From an IARC Expert Consultation. *J Med Virol*. 2025 Mar;97(3):e70310. [doi: 10.1002/jmv.70310](https://doi.org/10.1002/jmv.70310). [PMID: 40109087](https://pubmed.ncbi.nlm.nih.gov/40109087/).
17. Sheridan B, Irzaldy A, Heijnsdijk EAM, Dimitrova N, Senore C, Basu P, de Koning HJ. Prioritizing performance and outcome indicators for quality assessment of cancer screening programs in the EU. *Public Health*. 2025 Feb;239:185-192. [doi: 10.1016/j.puhe.2024.12.010](https://doi.org/10.1016/j.puhe.2024.12.010). [PMID: 39869999](https://pubmed.ncbi.nlm.nih.gov/39869999/).
18. Xu Y, Zhu S, Xia C, Yu H, Shi S, Chen K, He Y, Deng C, Jin H, Liu J, Fitzgerald R, Basu P, Chen W. Liquid biopsy-based multi-cancer early detection: an exploration road from evidence to implementation. *Sci Bull (Beijing)*. 2025 Sep 15;70(17):2852-2867. [doi: 10.1016/j.scib.2025.06.030](https://doi.org/10.1016/j.scib.2025.06.030). [PMID: 40670203](https://pubmed.ncbi.nlm.nih.gov/40670203/).
19. Almonte M, Ilbawi AM, Maza M, Saville M, Murillo R, Forestier M, Bloem P, Luciani S, Mikkelsen B. From commitments to action: the first global cervical cancer elimination forum. *Lancet Reg Health Am*. 2024 Jun 12;36:100812. [doi: 10.1016/j.lana.2024.100812](https://doi.org/10.1016/j.lana.2024.100812). [PMID: 38974379](https://pubmed.ncbi.nlm.nih.gov/38974379/).
20. Arbyn M, Cuschieri K, Bonde J, Schuurman R, Cocuzza C, Broeck DV, Zhao FH, Rezhake R, Gultekin M, de Sanjosé S, Canfell K, Hawkes D, Saville M, Hillemanns P, Dillner J, Berkhof J, Prétet JL, Gheit T, Clifford



- G, Basu P, Almonte M, Wentzensen N, Poljak M. Criteria for second generation comparator tests in validation of novel HPV DNA tests for use in cervical cancer screening. *J Med Virol.* 2024 Sep;96(9):e29881. [doi: 10.1002/jmv.29881](https://doi.org/10.1002/jmv.29881). [PMID: 39221498](https://pubmed.ncbi.nlm.nih.gov/39221498/).
21. Arrossi S, Straw C, Sanchez Antelo V, Paolino M, Baena A, Forestier M, Rol M, Almonte M. Implementation of WHO guidelines for cervical cancer screening, diagnosis and treatment: knowledge and perceptions of health providers from Argentina. *BMC Cancer.* 2024 Aug 12;24(1):996. [doi: 10.1186/s12885-024-12650-7](https://doi.org/10.1186/s12885-024-12650-7). [PMID: 39134975](https://pubmed.ncbi.nlm.nih.gov/39134975/).
 22. Asangbeh-Kerman SL, Davidović M, Taghavi K, Dhokotera T, Manasyan A, Sharma A, Jaquet A, Musick B, Twizere C, Chimbetete C, Murenzi G, Tweya H, Muhairwe J, Wools-Kaloustian K, Technau KG, Anastos K, Yotebieng M, Jousse M, Ezechi O, Orang'o O, Bosomprah S, Pierre Boni S, Basu P, Bohlius J; leDEA. Cervical cancer prevention and care in HIV clinics across sub-Saharan Africa: results of a facility-based survey. *J Int AIDS Soc.* 2024 Jul;27(7):e26303. [doi: 10.1002/jia2.26303](https://doi.org/10.1002/jia2.26303). [PMID: 38979918](https://pubmed.ncbi.nlm.nih.gov/38979918/).
 23. Downham L, Rol ML, Forestier M, Romero P, Mendoza L, Mongelós P, Picconi MA, Colucci MC, Padin VM, Flores AP, Zúñiga M, Ferrera A, Cabrera Y, Crispín MF, Ramirez AT, Cele L, Diop-Ndiaye H, Samaté D, Manga P, Thiam FB, Rodriguez MI, DSouza JP, Nyaga VN, Diop M, Sebitloane M, Sánchez GI, Teran C, Calderon A, Wiesner C, Murillo R, Herrero R, Baena A, Almonte M. Field experience with the 8-HPV-type oncoprotein test for cervical cancer screening among HPV-positive women living with and without HIV in LMICs. *Int J Cancer.* 2024 Apr 11. [doi: 10.1002/ijc.34953](https://doi.org/10.1002/ijc.34953). [PMID: 38602045](https://pubmed.ncbi.nlm.nih.gov/38602045/).
 24. Downham L, Jaafar I, Rol ML, Nyawira Nyaga V, Valls J, Baena A, Zhang L, Gunter MJ, Arbyn M, Almonte M. Accuracy of HPV E6/E7 oncoprotein tests to detect high-grade cervical lesions: a systematic literature review and meta-analysis. *Br J Cancer.* 2024 Mar;130(4):517-525. [doi: 10.1038/s41416-023-02490-w](https://doi.org/10.1038/s41416-023-02490-w). [PMID: 37973957](https://pubmed.ncbi.nlm.nih.gov/37973957/).
 25. Fokom Domgue J, Dille I, Gnangnon F, Kapambwe S, Bouchard C, Mbatani N, Gauroy E, Ambounda NL, Yu R, Sidibe F, Kamgno J, Traore B, Tebeu PM, Halle-Ekane G, Diomande MI, Dangou JM, Lecuru F, Adewole I, Plante M, Basu P, Shete S. Utility of colposcopy for the screening and management of cervical cancer in Africa: a cross-sectional analysis of providers' training and practices. *BMC Health Serv Res.* 2024;24(1):1619. Epub 20241218. [doi: 10.1186/s12913-024-11982-1](https://doi.org/10.1186/s12913-024-11982-1). [PMID: 39695604](https://pubmed.ncbi.nlm.nih.gov/39695604/).
 26. Lehtinen M, Bruni L, Elfström M, Gray P, Logel M, Mariz FC, Baussano I, Vänskä S, Franco EL, Dillner J. Scientific approaches toward improving cervical cancer elimination strategies. *Int J Cancer.* 2024;154(9):1537-48. [doi: 10.1002/ijc.34839](https://doi.org/10.1002/ijc.34839). [PMID: 38196123](https://pubmed.ncbi.nlm.nih.gov/38196123/).
 27. Mallafré-Larrosa M, Chandran A, Oswal K, Kataria I, Purushotham A, Sankaranarayanan R, Swaminathan R, Rebello R, Isaac R, Kuriakose M, Sullivan R, Basu P; ACCI Consortium. Improving access to cancer care among rural populations in India: Development of a validated tool for health system capacity assessment. *Cancer Med.* 2024 Jul;13(14):e7343. [doi: 10.1002/cam4.7343](https://doi.org/10.1002/cam4.7343). [PMID: 39039809](https://pubmed.ncbi.nlm.nih.gov/39039809/).



28. Mensah K, Mosquera I, Tisler A, Üuskula A, Firmino-Machado J, Lunet N, Nicula F, Tăut D, Baban A, Basu P; CBIG-SCREEN Consortium. Development and pilot implementation of a novel protocol to assess capacity and readiness of health systems to adopt HPV detection-based cervical cancer screening in Europe. *Health Res Policy Syst.* 2024 Aug 12;22(1):102. [doi: 10.1186/s12961-024-01190-y](https://doi.org/10.1186/s12961-024-01190-y). [PMID: 39135116](https://pubmed.ncbi.nlm.nih.gov/39135116/).
29. Mosquera I, Barajas CB, Theriault H, Benitez Majano S, Zhang L, Maza M, Luciani S, Carvalho AL, Basu P. Assessment of barriers to cancer screening and interventions implemented to overcome these barriers in 27 Latin American and Caribbean countries. *Int J Cancer.* 2024 Aug 15;155(4):719-730. [doi: 10.1002/ijc.34950](https://doi.org/10.1002/ijc.34950). [PMID: 38648380](https://pubmed.ncbi.nlm.nih.gov/38648380/).
30. Ramírez AT, Mesher D, Baena A, Salgado Y, Kasamatsu E, Cristaldo C, Álvarez R, Rojas FD, Ramírez K, Guyot J, Henríquez O, González Palma H, Flores B, Peñaranda J, Vero MJ, Robinson I, Rol ML, Rodríguez G, Terán C, Ferrera A, Picconi MA, Calderon A, Mendoza L, Wiesner C, Almonte M, Herrero R. Impact of knowledge of HPV positivity on cervical cytology performance in latin america. *J Natl Cancer Inst.* 2024 Nov 12:djae283. [doi: 10.1093/jnci/djae283](https://doi.org/10.1093/jnci/djae283). [PMID: 39531343](https://pubmed.ncbi.nlm.nih.gov/39531343/).
31. Wu T, Lucas E, Zhao F, Basu P, Qiao Y. Artificial intelligence strengthens cervical cancer screening - present and future. *Cancer Biol Med.* 2024;21(10):864-79. [doi: 10.20892/j.issn.2095-3941.2024.0198](https://doi.org/10.20892/j.issn.2095-3941.2024.0198). [PMID: 39297572](https://pubmed.ncbi.nlm.nih.gov/39297572/).
32. Baena A, Mesher D, Salgado Y, Martínez S, Villalba GR, Amarilla ML, Salgado B, Flores B, Bellido-Fuentes Y, Álvarez-Larraondo M, Valls J, Lora O, Virreira-Prout G, Figueroa J, Turcios E, Soilán AM, Ortega M, Celis M, González M, Venegas G, Terán C, Ferrera A, Mendoza L, Kasamatsu E, Murillo R, Wiesner C, Broutet N, Luciani S, Herrero R, Almonte M; ESTAMPA study group. Performance of visual inspection of the cervix with acetic acid (VIA) for triage of HPV screen-positive women: results from the ESTAMPA study. *Int J Cancer.* 2023 Apr 15;152(8):1581-1592. [doi: 10.1002/ijc.34384](https://doi.org/10.1002/ijc.34384). [PMID: 36451311](https://pubmed.ncbi.nlm.nih.gov/36451311/).
33. Clifford GM, Baussano I, Heideman DAM, Tshering S, Choden T, Lazzarato F, Tenet V, Franceschi S, Darragh TM, Tobgay T, Tshomo U. Human papillomavirus testing on self-collected samples to detect high-grade cervical lesions in rural Bhutan: The REACH-Bhutan study. *Cancer Med.* 2023 May;12(10):11828-11837. [doi: 10.1002/cam4.5851](https://doi.org/10.1002/cam4.5851). [PMID: 36999740](https://pubmed.ncbi.nlm.nih.gov/36999740/).
34. Hu SY, Zhao XL, Zhao FH, Wei LH, Zhou Q, Niyazi M, Liu JH, Wang CY, Li LY, Cheng XD, Duan XZ, Sauvaget C, Qiao YL, Sankaranarayanan R. Implementation of visual inspection with acetic acid and Lugol's iodine for cervical cancer screening in rural China. *Int J Gynaecol Obstet.* 2023 Feb;160(2):571-578. [doi: 10.1002/ijgo.14368](https://doi.org/10.1002/ijgo.14368). [PMID: 35871356](https://pubmed.ncbi.nlm.nih.gov/35871356/).
35. IARC; Department of Health and Health Service Executive of Ireland (2023). Best practices in cervical screening programmes: audit of cancers, legal and ethical frameworks, communication, and workforce



competencies. Lyon, France: International Agency for Research on Cancer (IARC Working Group Reports, No. 11). Available from: <https://publications.iarc.fr/625>.

36. IARC; Lalla Salma Foundation for Cancer Prevention and Treatment (2023). Implementation of a pilot cervical cancer screening programme integrated in routine primary health-care services in Benin, Côte d'Ivoire, and Senegal: report of a pilot project (Care4Afrique) in three African countries. Lyon, France: International Agency for Research on Cancer. Available from: <https://publications.iarc.fr/614>.
37. Mallafré-Larrosa M, Ritchie D, Papi G, Mosquera I, Mensah K, Lucas E, Bøje RB, Kirkegaard P, Andersen B, Basu P; CBIG-SCREEN Consortium. Survey of current policies towards widening cervical screening coverage among vulnerable women in 22 European countries. *Eur J Public Health*. 2023 Jun 1;33(3):502-508. doi: [10.1093/eurpub/ckad055](https://doi.org/10.1093/eurpub/ckad055). PMID: [37043751](https://pubmed.ncbi.nlm.nih.gov/37043751/).
38. Mosquera I, Barajas CB, Zhang L, Lucas E, Benitez Majano S, Maza M, Luciani S, Basu P, Carvalho AL. Assessment of organization of cervical and breast cancer screening programmes in the Latin American and the Caribbean states: The CanScreen5 framework. *Cancer Med*. 2023 Oct;12(19):19935-19948. doi: [10.1002/cam4.6492](https://doi.org/10.1002/cam4.6492). PMID: [37768035](https://pubmed.ncbi.nlm.nih.gov/37768035/).
39. Mosquera I, Todd A, Balaj M, Zhang L, Benitez Majano S, Mensah K, Eikemo TA, Basu P, Carvalho AL. Components and effectiveness of patient navigation programmes to increase participation to breast, cervical and colorectal cancer screening: A systematic review. *Cancer Med*. 2023 Jul;12(13):14584-14611. doi: [10.1002/cam4.6050](https://doi.org/10.1002/cam4.6050). PMID: [37245225](https://pubmed.ncbi.nlm.nih.gov/37245225/).
40. Ramírez AT, Valls J, Baena A, Rojas FD, Ramírez K, Álvarez R, Cristaldo C, Henríquez O, Moreno A, Reynaga DC, Palma HG, Robinson I, Hernández DC, Bardales R, Cardinal L, Salgado Y, Martínez S, González E, Guillén D, Fleider L, Tatti S, Villagra V, Venegas G, Cruz-Valdez A, Valencia M, Rodríguez G, Terán C, Picconi MA, Ferrera A, Kasamatsu E, Mendoza L, Calderon A, Luciani S, Broutet N, Darragh T, Almonte M, Herrero R; ESTAMPA Study Group. Performance of cervical cytology and HPV testing for primary cervical cancer screening in Latin America: an analysis within the ESTAMPA study. *Lancet Reg Health Am*. 2023 Sep 20;26:100593. doi: [10.1016/j.lana.2023.100593](https://doi.org/10.1016/j.lana.2023.100593). PMID: [37766799](https://pubmed.ncbi.nlm.nih.gov/37766799/).
41. Satyanarayanan SK, Kozlakidis Z. Editorial: Rising stars in infectious diseases-Surveillance, prevention and treatment: 2022. *Front Med (Lausanne)*. 2023 Jul 4;10:1234922. doi: [10.3389/fmed.2023.1234922](https://doi.org/10.3389/fmed.2023.1234922). PMID: [37469666](https://pubmed.ncbi.nlm.nih.gov/37469666/).
42. Taghavi K, Zhao F, Downham L, Baena A, Basu P. Molecular triaging options for women testing HPV positive with self-collected samples. *Front Oncol*. 2023 Sep 22;13:1243888. doi: [10.3389/fonc.2023.1243888](https://doi.org/10.3389/fonc.2023.1243888). PMID: [37810963](https://pubmed.ncbi.nlm.nih.gov/37810963/).
43. Valls J, Baena A, Venegas G, Celis M, González M, Sosa C, Santin JL, Ortega M, Soilán A, Turcios E, Figueroa J, Rodríguez de la Peña M, Figueredo A, Beracocha AV, Pérez N, Martínez-Better J, Lora O, Jiménez JY, Giménez D, Fleider L, Salgado Y, Martínez S, Bellido-Fuentes Y, Flores B, Tatti S, Villagra V,



Cruz-Valdez A, Terán C, Sánchez GI, Rodríguez G, Picconi MA, Ferrera A, Mendoza L, Calderón A, Murillo R, Wiesner C, Broutet N, Luciani S, Pérez C, Darragh TM, Jerónimo J, Herrero R, Almonte M; ESTAMPA study group. Performance of standardised colposcopy to detect cervical precancer and cancer for triage of women testing positive for human papillomavirus: results from the ESTAMPA multicentric screening study. *Lancet Glob Health*. 2023 Mar;11(3):e350-e360. doi: [10.1016/S2214-109X\(22\)00545-9](https://doi.org/10.1016/S2214-109X(22)00545-9). PMID: [36796982](https://pubmed.ncbi.nlm.nih.gov/36796982/).

44. Zhang L, Mosquera I, Lucas E, Rol ML, Carvalho AL, Basu P; CanScreen5 collaborators. CanScreen5, a global repository for breast, cervical and colorectal cancer screening programs. *Nat Med*. 2023 May;29(5):1135-1145. doi: [10.1038/s41591-023-02315-6](https://doi.org/10.1038/s41591-023-02315-6). PMID: [37106168](https://pubmed.ncbi.nlm.nih.gov/37106168/).
45. Benider A, Bendahhou K, Sauvaget C, Mrabti H, Selmouni F, Muwonge R, Alaoui L, Lucas E, Chami Y, Abousselham L, Bennani M, Errihani H, Sankaranarayanan R, Bekkali R, Basu P. Evolution of patterns of care for women with cervical cancer in Morocco over a decade. *BMC Cancer*. 2022 May 2;22(1):479. doi: [10.1186/s12885-022-09358-x](https://doi.org/10.1186/s12885-022-09358-x). PMID: [35501742](https://pubmed.ncbi.nlm.nih.gov/35501742/).
46. Correa RM, Baena A, Valls J, Colucci MC, Mendoza L, Rol M, Wiesner C, Ferrera A, Fellner MD, González JV, Basiletti JA, Mongelos P, Rodríguez de la Peña M, Saino A, Kasamatsu E, Velarde C, Macavilca N, Martínez S, Venegas G, Calderón A, Rodríguez G, Barrios H, Herrero R, Almonte M, Picconi MA; ESTAMPA Study Group. Distribution of human papillomavirus genotypes by severity of cervical lesions in HPV screened positive women from the ESTAMPA study in Latin America. *PLoS One*. 2022 Jul 29;17(7):e0272205. doi: [10.1371/journal.pone.0272205](https://doi.org/10.1371/journal.pone.0272205). PMID: [35905130](https://pubmed.ncbi.nlm.nih.gov/35905130/).
47. IARC (2022). Cervical cancer screening. *IARC Handb Cancer Prev*. 18:1–456. Available from: [IARC Publications Website - Cervical Cancer Screening](https://publications.iarc.fr/publication/2022-01-01/cervical-cancer-screening).
48. Lauby-Secretan B, Mackie A, Wentzensen N. The IARC Perspective on Cervical Cancer Screening. Reply. *N Engl J Med*. 2022 Feb 10;386(6):607-608. doi: [10.1056/NEJMc2119177](https://doi.org/10.1056/NEJMc2119177). PMID: [35139285](https://pubmed.ncbi.nlm.nih.gov/35139285/).
49. Rol ML, Picconi MA, Ferrera A, Sánchez GI, Hernández ML, Lineros J, Peraza A, Brizuela M, Mendoza L, Mongelós P, Cabrera Y, Rodríguez de la Peña M, Correa RM, Terán C, Colque Reynaga D, García L, Ramírez AT, Hernández-Nevarez P, Doimi F, Ramón M, Arias-Stella J, Zúñiga M, Villagra V, Bobadilla ML, Cardinal L, Valls J, Lucas E, Baena A, Fleider L, Venegas G, Cruz-Valdez A, Rodríguez G, Calderón A, Wiesner C, Luciani S, Broutet N, Herrero R, Almonte M. Implementing HPV testing in 9 Latin American countries: The laboratory perspective as observed in the ESTAMPA study. *Front Med (Lausanne)*. 2022 Nov 17;9:1006038. doi: [10.3389/fmed.2022.1006038](https://doi.org/10.3389/fmed.2022.1006038). PMID: [36465901](https://pubmed.ncbi.nlm.nih.gov/36465901/).
50. Ngwa W, Addai BW, Adewole I, Ainsworth V, Alaro J, Alatise OI, Ali Z, Anderson BO, Anorlu R, Avery S, Barango P, Bih N, Booth CM, Brawley OW, Dangou JM, Denny L, Dent J, Elmore SNC, Elzawawy A, Gashumba D, Geel J, Graef K, Gupta S, Gueye SM, Hammad N, Hessissen L, Ilbawi AM, Kambugu J, Kozlakidis Z, Manga S, Maree L, Mohammed SI, Msadabwe S, Mutebi M, Nakaganda A, Ndlovu N, Ndoh



K, Ndumbalo J, Ngoma M, Ngoma T, Ntirimira C, Rebbeck TR, Renner L, Romanoff A, Rubagumya F, Sayed S, Sud S, Simonds H, Sullivan R, Swanson W, Vanderpuye V, Wiafe B, Kerr D. Cancer in sub-Saharan Africa: a Lancet Oncology Commission. *Lancet Oncol.* 2022 Jun;23(6):e251-e312. doi: [10.1016/S1470-2045\(21\)00720-8](https://doi.org/10.1016/S1470-2045(21)00720-8). PMID: 35550267.

51. Selmouni F, Guy M, Muwonge R, Nassiri A, Lucas E, Basu P, Sauvaget C. Effectiveness of Artificial Intelligence-Assisted Decision-making to Improve Vulnerable Women's Participation in Cervical Cancer Screening in France: Protocol for a Cluster Randomized Controlled Trial (AppDate-You). *JMIR Res Protoc.* 2022 Aug 2;11(8):e39288. doi: [10.2196/39288](https://doi.org/10.2196/39288). PMID: 35771872.
52. Zhang L, Carvalho AL, Mosquera I, Wen T, Lucas E, Sauvaget C, Muwonge R, Arbyn M, Weiderpass E, Basu P. An international consensus on the essential and desirable criteria for an 'organized' cancer screening programme. *BMC Med.* 2022 Mar 23;20(1):101. doi: [10.1186/s12916-022-02291-7](https://doi.org/10.1186/s12916-022-02291-7). PMID: [35317783](https://pubmed.ncbi.nlm.nih.gov/35317783/).
53. Bouvard V, Wentzensen N, Mackie A, Berkhof J, Brotherton J, Giorgi-Rossi P, Kupets R, Smith R, Arrossi S, Bendahhou K, Canfell K, Chirenje ZM, Chung MH, Del Pino M, de Sanjosé S, Elfström M, Franco EL, Hamashima C, Hamers FF, Herrington CS, Murillo R, Sangrairang S, Sankaranarayanan R, Saraiya M, Schiffman M, Zhao F, Arbyn M, Prendiville W, Indave Ruiz BI, Mosquera-Metcalfe I, Lauby-Secretan B. The IARC Perspective on Cervical Cancer Screening. *N Engl J Med.* 2021 Nov 11;385(20):1908-1918. doi: [10.1056/NEJMSr2030640](https://doi.org/10.1056/NEJMSr2030640). PMID: 34758259.

TREATMENT AND CANCER SURVEILLANCE

1. Conzuelo Rodriguez G, Cremer ML, Muwonge R, Basu P. Use of Thermal Ablation in Low-Resource Settings: Experience From Three Multicenter Noninferiority Randomized Clinical Trials. *JCO Glob Oncol.* 2025 Jun;11:e2500050. doi: [10.1200/GO-25-00050](https://doi.org/10.1200/GO-25-00050). PMID: 40479636.
2. Fuady A, Kasempa C, Lucas E, Nyambe N, Rao DW, Tenet V, Broutet N, Muwonge R, Mwanahamuntu M, Baussano I, Parham GP, Basu P. Economic evaluation of thermal ablation compared to cryotherapy and loop diathermy in a screen-and-treat approach to cervical cancer, Zambia. *Bull World Health Organ.* 2025 Sep 1;103(9):530-540. doi: [10.2471/BLT.24.292792](https://doi.org/10.2471/BLT.24.292792). PMID: 40900929.
3. Pinder LF, Bertrand P, Fertitta V, Cahais V, Mwanahamuntu M, Nyambe N, Chisele S, Shibemba AL, McKay-Chopin S, Cuenin C, Lucas E, Korenjak M, Muwonge R, Ghantous A, Herceg Z, Parham GP, Zavadil J, Basu P, Gheit T. Vaginal microbiome composition in women with HIV undergoing treatment of cervical transformation zone in a screen and treat program in Zambia. *AIDS.* 2025 Jul 15;39(9):1303-1306. doi: [10.1097/QAD.0000000000004187](https://doi.org/10.1097/QAD.0000000000004187). PMID: 40568741.



4. Basu P, Mwanahamuntu M, Pinder LF, Muwonge R, Lucas E, Nyambe N, Chisele S, Shibemba AL, Sauvaget C, Sankaranarayanan R, Prendiville W, Parham GP. A portable thermal ablation device for cervical cancer prevention in a screen-and-treat setting: a randomized, noninferiority trial. *Nat Med*. 2024 Sep;30(9):2596-2604. [doi: 10.1038/s41591-024-03080-w](https://doi.org/10.1038/s41591-024-03080-w). [PMID: 38918630](https://pubmed.ncbi.nlm.nih.gov/38918630/).
5. Baena A, Paolino M, Villarreal-Garza C, Torres G, Delgado L, Ruiz R, Canelo-Aybar C, Song Y, Feliu A, Maza M, Jeronimo J, Espina C, Almonte M. Latin America and the Caribbean Code Against Cancer 1st Edition: Medical interventions including hormone replacement therapy and cancer screening. *Cancer Epidemiol*. 2023 Oct;86 Suppl 1:102446. [doi: 10.1016/j.canep.2023.102446](https://doi.org/10.1016/j.canep.2023.102446). [PMID: 37852728](https://pubmed.ncbi.nlm.nih.gov/37852728/).
6. Ibrahim Khalil A, Zhang L, Muwonge R, Sauvaget C, Basu P. Efficacy and safety of therapeutic HPV vaccines to treat CIN 2/CIN 3 lesions: a systematic review and meta-analysis of phase II/III clinical trials. *BMJ Open*. 2023 Oct 24;13(10):e069616. [doi: 10.1136/bmjopen-2022-069616](https://doi.org/10.1136/bmjopen-2022-069616). [PMID: 37879679](https://pubmed.ncbi.nlm.nih.gov/37879679/).
7. Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, Arbyn M, Basu P, Bray F, Vaccarella S. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. *Lancet Glob Health*. 2023 Feb;11(2):e197-e206. [doi: 10.1016/S2214-109X\(22\)00501-0](https://doi.org/10.1016/S2214-109X(22)00501-0). [PMID: 36528031](https://pubmed.ncbi.nlm.nih.gov/36528031/).
8. Zhang L, Sauvaget C, Mosquera I, Basu P. Efficacy, acceptability and safety of ablative versus excisional procedure in the treatment of histologically confirmed CIN2/3: A systematic review. *BJOG*. 2023 Jan;130(2):153-161. [doi: 10.1111/1471-0528.17251](https://doi.org/10.1111/1471-0528.17251). [PMID: 35689493](https://pubmed.ncbi.nlm.nih.gov/35689493/).
9. IARC and PAHO launch the 1st edition of the Latin America and the Caribbean Code Against Cancer. Available from: [IARC and PAHO launch the 1st edition of the Latin America and the Caribbean Code Against Cancer – IARC](#)
10. WHO Classification of Tumours, 5th Edition, Volume 4. Female Genital Tumours. IARC, 2020. Available from: [IARC Publications Website - Female Genital Tumours](#)